Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece

References

• ScottDLWolfeFHuizingaTWRheumatoid arthritisLancet201037697461094110820870100
   PubMed Web of Science ®Google Scholar
• WoolfADPflegerBBurden of major musculoskeletal conditionsBull World Health Organ200381964665614710506
   PubMed Web of Science ®Google Scholar
• WongRDavisAMBadleyEGrewalRMohammedMPrevalence of Arthritis and Rheumatic Diseases Around the World. A Growing Burden and Implications for Health Care NeedsTorontoArthritis Community Research and Evaluation (ACREU)2010 Available from: http://www.modelsofcare.ca/pdf/10-02.pdfAccessed November 22, 2014
   Google Scholar
• AndrianakosATrontzasPChristoyannisFESORDIG StudyPrevalence of rheumatic diseases in Greece: a cross-sectional population based epidemiological study. The ESORDIG StudyJ Rheumatol20033071589160112858464
   PubMed Web of Science ®Google Scholar
• AndrianakosATrontzasPChristoyannisFESORDIG Study GroupPrevalence and management of rheumatoid arthritis in the general population of Greece – the ESORDIG studyRheumatology (Oxford)200645121549155416690763
   PubMed Web of Science ®Google Scholar
• AndrianakosAAMiyakisSTrontzasPESORDIG study groupThe burden of the rheumatic diseases in the general adult population of Greece: the ESORDIG studyRheumatology (Oxford)200544793293815840597
   PubMed Web of Science ®Google Scholar
• MeenanRFYelinEHHenkeCJCurtisDLEpsteinWVThe costs of rheumatoid arthritis. A patient-oriented study of chronic disease costsArthritis Rheum1978217827833100122
   PubMed Web of Science ®Google Scholar
• LubeckDPSpitzPWFriesJFWolfeFMitchellDMRothSHA multicenter study of annual health service utilization and costs in rheumatoid arthritisArthritis Rheum19862944884933707626
   PubMed Web of Science ®Google Scholar
• WolfeFKleinhekselSMSpitzPWA multicenter study of hospitalization in rheumatoid arthritis. Frequency, medical-surgical admissions, and chargesArthritis Rheum19862956146193718553
   PubMed Web of Science ®Google Scholar
• LiangMHLarsonMThompsonMCosts and outcomes in rheumatoid arthritis and osteoarthritisArthritis Rheum19842755225296721884
   PubMed Web of Science ®Google Scholar
• YelinEWankeLAAn assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional declineArthritis Rheum19994261209121810366114
   PubMed Web of Science ®Google Scholar
• GabrielSECrowsonCSCampionMEO’FallonWMDirect medical costs unique to people with arthritisJ Rheumatol19972447197259101508
   PubMed Web of Science ®Google Scholar
• ClarkeAEZowallHLevintonCDirect and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year studyJ Rheumatol1997246105110609195508
   PubMed Web of Science ®Google Scholar
• van JaarsveldCHJacobsJWSchrijversAJHeurkensAHHaanenHCBijlsmaJWDirect cost of rheumatoid arthritis during the first six years: a cost-of-illness studyBr J Rheumatol19983788378479734674
   PubMedGoogle Scholar
• JonssonBRehnbergCBorgquistLLarssonSELocomotion status and costs in destructive rheumatoid arthritis. A comprehensive study of 82 patients from a population of 13,000Acta Orthop Scand19926322072121590060
   PubMed Web of Science ®Google Scholar
• MerkesdalSRuofJSchöffskiOBernittKZeidlerHMauWIndirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of diseaseArthritis Rheum200144352853411263766
   PubMed Web of Science ®Google Scholar
• FurneriGMantovaniLGBelisariASystematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritisClin Exp Rheumatol2012304 Suppl 73S72S8423072761
   PubMed Web of Science ®Google Scholar
• BoonenASeverensJLThe burden of illness of rheumatoid arthritisClin Rheumatol201130Suppl 1S3S821359507
   PubMed Web of Science ®Google Scholar
• SinghJAFurstDEBharatA2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care Res (Hoboken)201264562563922473917
   PubMed Web of Science ®Google Scholar
• SaagKGTengGGPatkarNMAmerican College of RheumatologyAmerican College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisArthritis Rheum200859676278418512708
   PubMed Web of Science ®Google Scholar
• National Organizations for Medicines. Protocols for Medicine and Medical activities: Rheumatoid Arthritis v1.0 Accessed at http://www.eof.gr/c/document_library/get_file?p_l_id=34765&folderId=34627&name=DLFE-1514.pdfon November 22, 2014 Greek.
   Google Scholar
• Hellenic Rheumatology Society. Therapeutic Prescription Protocols: 08-006A. Established Rheumatoid Arthritis” Accessed at: http://www.ere.gr/_pdf/08_006_A.pdfon November 22, 2014 Greek
   Google Scholar
• BreedveldFThe value of early intervention in RA – a window of opportunityClin Rheumatol201130Suppl 1S33S3921350796
   PubMed Web of Science ®Google Scholar
• SouliotisKPapageorgiouMPolitiAIoakeimidisDSidiropoulosPBarriers to accessing biologic treatment for rheumatoid arthritis in Greece: the unseen impact of the fiscal crisis – the Health Outcomes Patient Environment (HOPE) studyRheumatol Int2014341253324057144
   PubMed Web of Science ®Google Scholar
• Escudero-VilaplanaVRamírez-HerraizETrovato-LópezNInfluence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritisJ Pharm Pharm Sci201215335536022974785
   PubMed Web of Science ®Google Scholar
• BlomMKievitWKuperHHFrequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practiceArthritis Care Res (Hoboken)20106291335134120506128
   PubMed Web of Science ®Google Scholar
• BlumeSWFoxKMJosephGChuangCCThomasJGandraSRTumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management settingAdv Ther201330551752723740359
   PubMed Web of Science ®Google Scholar
• BonafedeMMGandraSRFoxKMWilsonKLTumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiationJ Med Econ201215463564322332705
   PubMedGoogle Scholar
• FisherMDWatsonCFoxKMChenYWGandraSRDosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care populationCurr Med Res Opin201329556156823489410
   PubMed Web of Science ®Google Scholar
• HarrisonDJHuangXGlobeDDosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritisAm J Health Syst Pharm201067151281128720651319
   PubMed Web of Science ®Google Scholar
• MalottkiKBartonPTsourapasAAdalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluationHealth Technol Assess20111514127821439251
   PubMed Web of Science ®Google Scholar
• MootsRJHaraouiBMatucci-CerinicMDifferences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practiceClin Exp Rheumatol2011291263421345289
   PubMed Web of Science ®Google Scholar
• OllendorfDAKlingmanDHazardERaySDifferences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care populationClin Ther200931482583519446156
   PubMed Web of Science ®Google Scholar
• Ariza-ArizaRNavarro-SarabiaFHernández-CruzBRodríguez-ArboleyaLNavarro-CompánVToyosJDose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic reviewRheumatology (Oxford)200746352953217012439
   PubMed Web of Science ®Google Scholar
• SchabertVFBruceBFerrufinoCFDisability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness studyCurr Med Res Opin201228456958022236091
   PubMed Web of Science ®Google Scholar
• Ramírez-HerráizEEscudero-VilaplanaVAlañón-PlazaEEfficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practiceClin Exp Rheumatol201331455956523710583
   PubMed Web of Science ®Google Scholar
• HuangXGuNYFoxKMHarrisonDJGlobeDComparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practiceCurr Med Res Opin20102671637164520429830
   PubMed Web of Science ®Google Scholar
• KentikelenisAKaranikolosMPapanicolasIBasuSMcKeeMStucklerDHealth effects of financial crisis: omens of a Greek tragedyLancet201137898011457145821988763
   PubMed Web of Science ®Google Scholar
• KumarPBanikSPharmacotherapy options in rheumatoid arthritisClin Med Insights Arthritis Musculoskelet Disord20136354323997576
   PubMedGoogle Scholar
• GartlehnerGHansenRAJonasBLThiedaPLohrKNThe comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysisJ Rheumatol200633122398240817225293
   PubMed Web of Science ®Google Scholar
• Greek Ministry of HealthDrug Price Bulletin Accessed at November 2014; Available at: www.yyka.gov.gr/Accessed November 22, 2014 Greek
   Google Scholar
• MiglioreABizziEMassafraUCan Cyclosporine-A associated to methotrexate maintain remission induced by anti-TNF agents in rheumatoid arthritis patients? (Cynar pilot study)Int J Immunopathol Pharmacol201023378379020943048
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyAnnex I. Summary of Product Characteristics [Embrel 25 mg powder and solvent for solution for injection]LondonEuropean Medicines Agency Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdfAccessed November 22, 2014
   Google Scholar
• European Medicines AgencyAnnex I. Summary of Product Characteristics [Remicade 100 mg powder for concentrate for solution for infusion]LondonEuropean Medicines Agency Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdfAccessed November 22, 2014
   Google Scholar
• European Medicines AgencyAnnex I. Summary of Product Characteristics [Humira 40 mg/0.8 ml for injection for paediatric use]LondonEuropean Medicines Agency Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdfAccessed November 22, 2014
   Google Scholar
• FlouriIMarkatseliTEVoulgariPVComparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survivalSemin Arthritis Rheum201443444745724012040
   PubMed Web of Science ®Google Scholar
• RahmanMUStrusbergIGeusensPDouble-blinded infliximab dose escalation in patients with rheumatoid arthritisAnn Rheum Dis20076691233123817392352
   PubMed Web of Science ®Google Scholar
• BonafedeMJosephGJPrincicNHarrisonDJAnnual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitisJ Med Econ20131691120112823808901
   PubMedGoogle Scholar
• LiuYWuEQBensimonAGCost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritisAdv Ther201229762063422843208
   PubMed Web of Science ®Google Scholar
• TsaoNWBansbackNJShojaniaKMarraCAThe issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritisBest Pract Res Clin Rheumatol201226565967623218430
   PubMed Web of Science ®Google Scholar
• BansbackNJRegierDAAraRAn overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonistsDrugs200565447349615733011
   PubMed Web of Science ®Google Scholar
• ChenYFJobanputraPBartonPA systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectivenessHealth Technol Assess20061042iiiivxi17049139
   PubMed Web of Science ®Google Scholar
• DoanQVChiouCFDuboisRWReview of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritisJ Manag Care Pharm200612755556916981801
   PubMed Web of Science ®Google Scholar
• SullivanSDAlfonso-CristanchoRCarlsonJMallyaURingoldSEconomic consequences of sequencing biologics in rheumatoid arthritis: a systematic reviewJ Med Econ201316339139623298329
   PubMedGoogle Scholar
• HerMKavanaughACritical analysis of economic tools and economic measurement applied to rheumatoid arthritisClin Exp Rheumatol2012304 Suppl 73S107SS11123078839
   PubMed Web of Science ®Google Scholar
• IannazzoSDe FrancescoMGomez-UlloaDBenucciMA review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritisExpert Rev Pharmacoecon Outcomes Res201313445546823977974
   PubMed Web of Science ®Google Scholar
• SullivanSDMauskopfJAAugustovskiFBudget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task ForceValue Health201417151424438712
   PubMed Web of Science ®Google Scholar
• EscalanteAHaasRWdel RincónIMeasurement of global functional performance in patients with rheumatoid arthritis using rheumatology function testsArthritis Res Ther200464R315R32515225367
   PubMed Web of Science ®Google Scholar